Volume 16, Issue 53 (August 2006)
J Mazandaran Univ Med Sci 2006, 16(53): 25-31 |
Back to browse issues page
Abstract: (26730 Views)
Background and purpose: Low extrapyramidal symptoms, weight gain, increased fasting blood sugar and cholestrole are some of the side effects of antipsychotic drugs that can be dangerous for patients. Atypical antipsychotics like olanzapine have little extrapyramidal side effects, but they may induce weight gain and increase FBS.
Materials and Methods: In this simple randomized double blind chincal trial, 80 admitted patients of psychiatric wards of Noor hospital were randomly divided in two groups, 40 in each. Patients who had past history of diabetes melltus and family history of DM in the first degree relations and/or had undergone diabetogenic drugs thrapy from 15 days before this research or had fatness (BMI > 28) were excluded from study. These two groups were statistically matched for age, sex and diagnosis. Primaly FBS was measured 24 to 48 hours after admission and secondary FBS is measured 1 month after the beginning of the treatment.
Results: Mean FBS increased in both groups. In typical antipsychotics group, the mean of primary FBS was 89.3 ± 11.1 and the mean of secondary FBS was 94.9 ± 12.6. Paired t-test showed that this difference is statistically significant (t = 206 , p=0.01) and in olanzapine group the mean of primary and secondary FBS were 94.9 ± 14.35 and 101.8 ± 22.4 respectively. Paired t-test showed that this difference is statistically significant too (t = 2.44 , p= 0.01). Medium and high potent typical antipsychotics and olanzapine showed significant changes in FBS, however, the differences were not meaningful between these two groups (t = 0.38 , p = 0.7).
Conclusion: Although both typical antisychotic (medium and high potent) and olanzapine show significant difference in increasing FBS but the difference between these two, groups for increasing FBS were not meaningful. Therefore, case reports are not sufficient for assessing the effects of olanzapine on fasting blood sugar.
Materials and Methods: In this simple randomized double blind chincal trial, 80 admitted patients of psychiatric wards of Noor hospital were randomly divided in two groups, 40 in each. Patients who had past history of diabetes melltus and family history of DM in the first degree relations and/or had undergone diabetogenic drugs thrapy from 15 days before this research or had fatness (BMI > 28) were excluded from study. These two groups were statistically matched for age, sex and diagnosis. Primaly FBS was measured 24 to 48 hours after admission and secondary FBS is measured 1 month after the beginning of the treatment.
Results: Mean FBS increased in both groups. In typical antipsychotics group, the mean of primary FBS was 89.3 ± 11.1 and the mean of secondary FBS was 94.9 ± 12.6. Paired t-test showed that this difference is statistically significant (t = 206 , p=0.01) and in olanzapine group the mean of primary and secondary FBS were 94.9 ± 14.35 and 101.8 ± 22.4 respectively. Paired t-test showed that this difference is statistically significant too (t = 2.44 , p= 0.01). Medium and high potent typical antipsychotics and olanzapine showed significant changes in FBS, however, the differences were not meaningful between these two groups (t = 0.38 , p = 0.7).
Conclusion: Although both typical antisychotic (medium and high potent) and olanzapine show significant difference in increasing FBS but the difference between these two, groups for increasing FBS were not meaningful. Therefore, case reports are not sufficient for assessing the effects of olanzapine on fasting blood sugar.
Type of Study: Research(Original) |
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |